Response
We appreciate the comments of Christopher Nessel, and we are glad that as a clinician scientist in industry, he concurs with the synergistic potential of academic-industrial partnerships we have described. 1 Our "exhortation" to perform data analysis and interpretation independent of the sponsor, is, we believe, a fundamental tenant of this partnership. Hence, in our view, each partner or shareholder should possess the final data set emerging from the research, and performing replicate analysis and confirmation of the results provides eloquent and transparent testimony as to the study's integrity.
This, and other issues associated with previous protocol publication with access from the public domain can, in our view, only enhance public and professional confidence in the results of collaborative clinical investigation sponsored by industry, which shall surely remain an important element in future scientific advances. 2 
